{
    "nct_id": "NCT04814615",
    "official_title": "A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications",
    "inclusion_criteria": "1. Male or female â‰¥ 21 years of age\n2. Histologically/immunohistochemistry-confirmed CD38-positive multiple myeloma\n3. At least one tumor lesion on CT, MRI, or FDG PET/CT within 90 days of protocol enrollment\n4. ECOG performance status 0 to 2\n5. Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n2. Life expectancy < 12 months\n3. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.\n4. History of anaphylactic reaction to humanized or human antibodies.",
    "miscellaneous_criteria": ""
}